Mark Shoemaker

1.1k total citations
11 papers, 931 citations indexed

About

Mark Shoemaker is a scholar working on Molecular Biology, Pharmacology and Cancer Research. According to data from OpenAlex, Mark Shoemaker has authored 11 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Pharmacology and 4 papers in Cancer Research. Recurrent topics in Mark Shoemaker's work include Cancer, Lipids, and Metabolism (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Inflammatory mediators and NSAID effects (2 papers). Mark Shoemaker is often cited by papers focused on Cancer, Lipids, and Metabolism (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Inflammatory mediators and NSAID effects (2 papers). Mark Shoemaker collaborates with scholars based in United States and Canada. Mark Shoemaker's co-authors include Isaac Cohen, Michael J. Campbell, Michael J. Campbell, Emma Shtivelman, Corina Marx, Mary Tagliaferri, Christopher C. Benz, Stephen C. Benz, Kelly Adduci and Laura J. Esserman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Mark Shoemaker

11 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Shoemaker United States	10	483	296	210	182	165	11	931
Kun‐Hung Shen Taiwan	19	531 1.1×	195 0.7×	171 0.8×	152 0.8×	166 1.0×	35	1.1k
Malisetty V. Swamy United States	15	719 1.5×	267 0.9×	176 0.8×	103 0.6×	119 0.7×	20	1.3k
Zhi Dai China	20	975 2.0×	370 1.3×	170 0.8×	123 0.7×	189 1.1×	59	1.9k
R Lubet United States	16	685 1.4×	230 0.8×	259 1.2×	62 0.3×	85 0.5×	32	1.5k
Benjaporn Buranrat Thailand	15	378 0.8×	136 0.5×	124 0.6×	112 0.6×	107 0.6×	82	791
Govindaraj Sharmila India	15	508 1.1×	182 0.6×	90 0.4×	163 0.9×	39 0.2×	23	964
Zeyad D. Nassar Australia	24	582 1.2×	364 1.2×	69 0.3×	175 1.0×	80 0.5×	48	1.2k
E A Hudson United Kingdom	14	720 1.5×	145 0.5×	81 0.4×	174 1.0×	59 0.4×	18	1.4k
Xuanxuan Dai China	23	683 1.4×	239 0.8×	64 0.3×	77 0.4×	106 0.6×	40	1.2k

Countries citing papers authored by Mark Shoemaker

Since Specialization

Citations

This map shows the geographic impact of Mark Shoemaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Shoemaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Shoemaker more than expected).

Fields of papers citing papers by Mark Shoemaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Shoemaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Shoemaker. The network helps show where Mark Shoemaker may publish in the future.

Co-authorship network of co-authors of Mark Shoemaker

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Shoemaker. A scholar is included among the top collaborators of Mark Shoemaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Shoemaker. Mark Shoemaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

King, Frank W., Sylvia Fong, Chandi Griffin, et al.. (2009). Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress. PLoS ONE. 4(9). e7283–e7283. 74 indexed citations

Zhao, Xiaoyue, Chandi Griffin, Richard E. Staub, et al.. (2009). Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid. International Journal of Cancer. 127(5). 1209–1219. 29 indexed citations

Fong, Sylvia, Mark Shoemaker, Alvin Lo, et al.. (2008). Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells. Cancer Biology & Therapy. 7(4). 577–586. 38 indexed citations

Rugo, Hope S., Emma Shtivelman, Alejandra Perez, et al.. (2006). Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment. 105(1). 17–28. 84 indexed citations

Campbell, Michael J., Laura J. Esserman, Yamei Zhou, et al.. (2006). Breast Cancer Growth Prevention by Statins. Cancer Research. 66(17). 8707–8714. 286 indexed citations

Shoemaker, Mark, et al.. (2005). In vitro anticancer activity of twelve Chinese medicinal herbs. Phytotherapy Research. 19(7). 649–651. 197 indexed citations

Shoemaker, Mark, Isaac Cohen, & Michael J. Campbell. (2004). Reduction of MTT by aqueous herbal extracts in the absence of cells. Journal of Ethnopharmacology. 93(2-3). 381–384. 72 indexed citations

Esserman, L., et al.. (2004). Breast cancer inhibition by statins. Journal of Clinical Oncology. 22(14_suppl). 1003–1003. 10 indexed citations

Esserman, L., et al.. (2004). Breast cancer inhibition by statins. Journal of Clinical Oncology. 22(14_suppl). 1003–1003. 5 indexed citations

10.

Campbell, Michael J., et al.. (2003). Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.. PubMed. 22(6C). 3843–52. 59 indexed citations

11.

Cohen, Jack S., Robbe C. Lyon, Paula Faustino, et al.. (1986). Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy.. PubMed. 46(8). 4087–90. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact